Bright Minds Biosciences Inc. (DRUG)

USD 38.03

(-4.33%)

Market Cap (In USD)

264.25 Million

Revenue (In USD)

-

Net Income (In USD)

-7.37 Million

Avg. Volume

106.48 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.93-79.02
PE
-
EPS
-
Beta Value
1.132
ISIN
CA10919W4056
CUSIP
10919W108
CIK
1827401
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Ian McDonald
Employee Count
-
Website
https://brightmindsbio.com
Ipo Date
2021-03-22
Details
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.